Myriad Genetics, Inc. MYGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -129.10M | -112.60M | -399.90M | -365.90M | -400.50M |
| Total Depreciation and Amortization | 50.20M | 50.20M | 51.80M | 53.70M | 55.90M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 41.80M | 45.10M | 365.90M | 333.30M | 384.30M |
| Change in Net Operating Assets | 17.20M | 25.00M | -15.40M | -19.30M | -41.90M |
| Cash from Operations | -19.90M | 7.70M | 2.40M | 1.80M | -2.20M |
| Capital Expenditure | -14.00M | -15.00M | -15.70M | -15.60M | -14.50M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | 0.00 |
| Other Investing Activities | -3.80M | -6.90M | -9.90M | -11.80M | -12.80M |
| Cash from Investing | -17.80M | -21.90M | -25.60M | -27.40M | -27.30M |
| Total Debt Issued | 0.00 | 125.00M | 125.00M | 165.00M | 185.00M |
| Total Debt Repaid | -100.00K | -60.10M | -60.00M | -80.50M | -100.00M |
| Issuance of Common Stock | 3.40M | 3.40M | 3.30M | 3.30M | 5.60M |
| Repurchase of Common Stock | -4.70M | -4.80M | -4.40M | -7.30M | -7.30M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.90M | -16.30M | -16.30M | -16.30M | -8.80M |
| Cash from Financing | -9.30M | 47.20M | 47.60M | 64.20M | 74.50M |
| Foreign Exchange rate Adjustments | 0.00 | 100.00K | 600.00K | 800.00K | 0.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -47.00M | 33.10M | 25.00M | 39.40M | 45.00M |